Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 252 Cr.
- Current Price ₹ 194
- High / Low ₹ 625 / 150
- Stock P/E
- Book Value ₹ 8.56
- Dividend Yield 0.00 %
- ROCE -9.77 %
- ROE -161 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 51.1 to 38.4 days.
- Promoter holding has increased by 2.47% over last quarter.
Cons
- Stock is trading at 22.7 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.6%
- Company has a low return on equity of -85.2% over last 3 years.
- Promoter holding has decreased over last 3 years: -25.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39 | 46 | 50 | 59 | 59 | 77 | 62 | 80 | 93 | 108 | 126 | 131 | |
| 33 | 38 | 43 | 51 | 54 | 69 | 61 | 71 | 91 | 100 | 131 | 149 | |
| Operating Profit | 6 | 8 | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 9 | -5 | -18 |
| OPM % | 15% | 16% | 14% | 14% | 9% | 10% | 1% | 12% | 3% | 8% | -4% | -14% |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 2 | 14 | |
| Interest | 2 | 2 | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 6 | 4 | 7 |
| Depreciation | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 5 |
| Profit before tax | 3 | 4 | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | -12 | -16 |
| Tax % | 21% | 33% | 22% | 31% | 19% | 11% | -28% | 15% | -23% | 185% | 14% | -0% |
| 3 | 3 | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | -14 | -16 | |
| EPS in Rs | 2.24 | 2.56 | 2.90 | 2.66 | 2.31 | 3.69 | -4.59 | 2.24 | -0.85 | -0.47 | -11.60 | -12.74 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 28% |
| 3 Years: | 18% |
| 1 Year: | -53% |
| Return on Equity | |
|---|---|
| 10 Years: | -36% |
| 5 Years: | -69% |
| 3 Years: | -85% |
| Last Year: | -161% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 13 |
| Reserves | -19 | -17 | -4 | -3 | -7 | -3 | -7 | -4 | -5 | 7 | -3 | -2 |
| 70 | 69 | 56 | 75 | 62 | 64 | 77 | 70 | 72 | 76 | 71 | 86 | |
| 11 | 11 | 17 | 20 | 27 | 31 | 34 | 34 | 37 | 38 | 49 | 41 | |
| Total Liabilities | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| 33 | 34 | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 41 | 47 | 50 | |
| CWIP | 0 | 0 | 6 | 11 | 12 | 14 | 14 | 4 | 7 | 7 | 9 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 40 | 39 | 41 | 59 | 47 | 56 | 68 | 62 | 61 | 85 | 73 | 81 | |
| Total Assets | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 6 | 4 | -10 | 12 | 5 | 7 | -0 | 10 | -1 | 5 | -24 | |
| -0 | -3 | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -0 | -15 | -5 | |
| 2 | -2 | 0 | 17 | -12 | 1 | 6 | -13 | -1 | 20 | -9 | 32 | |
| Net Cash Flow | 2 | -0 | 1 | 4 | -2 | 2 | 12 | -16 | 2 | 18 | -19 | 3 |
| Free Cash Flow | -0 | 2 | 3 | -16 | 10 | 2 | 6 | -3 | 4 | -2 | -8 | -30 |
| CFO/OP | 8% | 73% | 62% | -120% | 251% | 71% | 885% | -5% | 390% | 1% | -138% | 136% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 33 | 35 | 34 | 43 | 51 | 61 | 61 | 51 | 59 | 56 | 38 |
| Inventory Days | 287 | 227 | 319 | 338 | 311 | 313 | 268 | 254 | 227 | 205 | 208 | 200 |
| Days Payable | 150 | 100 | 112 | 125 | 117 | 162 | 149 | 168 | 137 | 114 | 93 | 129 |
| Cash Conversion Cycle | 172 | 160 | 242 | 247 | 236 | 202 | 179 | 147 | 141 | 149 | 171 | 109 |
| Working Capital Days | -131 | -103 | -213 | -63 | -24 | -19 | -99 | -118 | -81 | -172 | -147 | -162 |
| ROCE % | 8% | 9% | 9% | 9% | 6% | 9% | -0% | 11% | 2% | 8% | -9% | -10% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Count ・Standalone data |
|
||||||||||
| Service Revenue Weightage (as % of Turnover) % ・Standalone data |
|||||||||||
| Herbarium Plant Varieties Count ・Standalone data |
|||||||||||
| Number of Certified Students / Alumni (USA Academy) Count |
|||||||||||
| Number of Major Distribution Depots Count ・Standalone data |
|||||||||||
| Number of SKUs Count |
|||||||||||
| R&D Expenditure as % of Turnover % ・Standalone data |
|||||||||||
| India E-commerce Revenue Growth % |
|||||||||||
| Number of Treatment Centers and Wellness Clinics Count |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
25 May - FY26 revenue rose to Rs145.4 Cr; KAL will acquire 26% stake in Ayurvedagram and targets Rs200 Cr FY27.
-
Announcement under Regulation 30 (LODR)-Change in Management
25 May - Board approved FY2026 audited results and appointed internal and cost auditors on May 25, 2026.
- Results - Financial Results For The Year Ended 31St March 2026 25 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th May 2026
25 May - Board approved FY26 audited standalone and consolidated results; appointed internal and cost auditors for FY27.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2018TranscriptAI SummaryPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants